Cumulus Neuroscience demonstrated that unsupervised at-home EEG and cognitive testing via the NeuLogiQ platform achieves high adherence (77-89%) and usability in both cognitively healthy and Alzheimer's disease populations over 52 weeks. This validates remote digital biomarkers as feasible alternatives to clinic-based neurological assessment, with implications for trial design and longitudinal cognitive monitoring.
Key Points
- At-home EEG and cognitive tests achieved 77-89% adherence over 52 weeks
- 119 participants (59 with Alzheimer's disease) completed 99.7% of initiated sessions
- Self-setup wireless EEG headset paired with gamified cognitive testing shows clinical feasibility
Longevity Analysis
Early detection and tracking of cognitive decline depend on repeated, accessible measurement of brain function over extended periods. Clinic-based assessment creates friction that limits frequency and consistency—barriers that undermine the longitudinal data needed to distinguish normal aging from pathological change. Remote EEG and neurocognitive assessment removes logistical interference, enabling individuals and clinicians to decode emerging cognitive signals with greater granularity and consistency. High adherence in both healthy and diseased populations indicates this approach can support earlier intervention windows, where the most meaningful optimization opportunities exist. For pharmaceutical development, frequent digital biomarkers reduce noise and site burden, potentially accelerating identification of meaningful cognitive changes.
Original published by Longevity.Technology.